<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vsp</journal-id><journal-title-group><journal-title xml:lang="ru">Вопросы современной педиатрии</journal-title><trans-title-group xml:lang="en"><trans-title>Current Pediatrics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-5527</issn><issn pub-type="epub">1682-5535</issn><publisher><publisher-name>Издательство «ПедиатрЪ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15690/vsp.v18i5.2058</article-id><article-id custom-type="elpub" pub-id-type="custom">vsp-2232</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group></article-categories><title-group><article-title>Поражение сердечно-сосудистой системы при мукополисахаридозе I типа: клинические случаи</article-title><trans-title-group xml:lang="en"><trans-title>Damages of Cardiovascular System at Mucopolysaccharidosis Type I: Clinical Cases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7336-4102</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васичкина</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasichkina</surname><given-names>Elena S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Васичкина Елена Сергеевна - доктор медицинских наук, главный научный сотрудник, руководитель НИО сердечно-сосудистых заболеваний у детей, профессор кафедры детских болезней НМИЦ им. В.А. Алмазова.</p><p>197341, Санкт-Петербург ул. Аккуратова д. 2, тел.: +7 (812) 702-68-50</p></bio><bio xml:lang="en"><p>Saint Petersburg</p></bio><email xlink:type="simple">Vasichkinalena@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1311-2020</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вершинина</surname><given-names>Т. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Vershinina</surname><given-names>Tatyana L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0842-9560</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковальчук</surname><given-names>Т. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovalchuk</surname><given-names>Tatyana S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8007-1447</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Блинова</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Blinova</surname><given-names>Ekaterina N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1767-7707</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малкина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Malkina</surname><given-names>Elizaveta V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9948-7303</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Первунина</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Pervunina</surname><given-names>Tatyana M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр им. В.А. Алмазова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>05</day><month>01</month><year>2020</year></pub-date><volume>18</volume><issue>5</issue><fpage>346</fpage><lpage>353</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Васичкина Е.С., Вершинина Т.Л., Ковальчук Т.С., Блинова Е.Н., Малкина Е.В., Первунина Т.М., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Васичкина Е.С., Вершинина Т.Л., Ковальчук Т.С., Блинова Е.Н., Малкина Е.В., Первунина Т.М.</copyright-holder><copyright-holder xml:lang="en">Vasichkina E.S., Vershinina T.L., Kovalchuk T.S., Blinova E.N., Malkina E.V., Pervunina T.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vsp.spr-journal.ru/jour/article/view/2232">https://vsp.spr-journal.ru/jour/article/view/2232</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Поражение сердца при мукополисахаридозе (МПС) I типа, синдроме Гурлер, имеет разные фенотипические проявления.</p><p>Описание клинического случая. В первом случае симптомы заболевания указывали на наличие остро возникшей тяжелой сердечной недостаточности, которая была подтверждена лабораторными и инструментальными методами диагностики. При эхокардиографии выявлены дилатация левых камер сердца и снижение сократительной способности левого желудочка. Нетипичное течение заболевания с отсутствием положительной динамики на фоне поликомпонентной терапии сердечной недостаточности позволило заподозрить заболевание обмена веществ и подтвердить его с помощью тандемной масс-спектрометрии и генетического анализа. Это, в свою очередь, привело к раннему началу ферментозаместительной терапии и аллогенной трансплантации костного мозга, что благоприятно сказалось на исходе заболевания. Во втором примере представлен классический вариант развития МПС I типа, клинические проявления которого в виде патологии опорно-двигательного аппарата, ЛОР-органов позволили диагностировать и подтвердить болезнь с помощью тандемной масс-спектрометрии и генетического анализа в возрасте 3 лет. Патология сердца в виде уплотнения створок митрального клапана с регургитацией 2-й степени и стеноз аорты были диагностированы позже. Раннее начало терапии, на наш взгляд, должно приостановить прогрессирование поражения сердца.</p></sec><sec><title>Заключение</title><p>Заключение. Описаны различные клинические варианты патологии сердца при МПС I типа. Показана необходимость постоянного контроля за состоянием сердечно-сосудистой системы у детей с МПС I типа. Отмечено, что поражение сердца может быть первым проявлением заболевания.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Cardiac involvement in patients with mucopolysaccharidosis (MPS) type I, or Hurler syndrome, has various phenotypes.</p><p>Clinical Case Description. In the first case symptoms were indicative of acute severe heart failure which was confirmed by laboratory and instrumental diagnostic methods. Left heart chambers dilatation and left ventricular hypocontractility were revealed on echocardiography. Atypical disease course with no improvement on multicomponent therapy of heart failure let us to think about metabolic disease, so we confirmed it with tandem mass spectrometry and molecular genetic testing. Therefore this led to timely enzyme replacement therapy onset and allogeneic bone marrow transplantation that positively affect the disease outcome. The second case showed classic course of MPS I. Its clinical signs such as musculoskeletal and ENT-organ manifestations allowed us to diagnosis and later confirm it by tandem mass spectrometry and molecular genetic testing at the age of 3. The cardiac pathology presented by mitral valve leaflets thickening and 2nd degree regurgitation has been diagnosed later. In our view, early treatment onset should slow down the progression of heart damage.</p></sec><sec><title>Conclusion</title><p>Conclusion. Several clinical variants of cardiac pathology at MPS I are presented. The need of constant cardiovascular system monitoring in children with MPS I is shown. It is also mentioned that cardiac pathology can be the first manifestation of the disease.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мукополисахаридоз</kwd><kwd>дети</kwd><kwd>сердечная недостаточность</kwd><kwd>кардиомиопатии</kwd><kwd>ферментозаместительная терапия</kwd><kwd>диагностика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>mucopolysaccharidosis</kwd><kwd>children</kwd><kwd>heart failure</kwd><kwd>cardiomyopathies</kwd><kwd>enzyme replacement therapy</kwd><kwd>diagnostics</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Не указан</funding-statement><funding-statement xml:lang="en">Not specified</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Boffi L, Russo P Limongelli G. Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists. Ital J Pediatr. 2018;44 (Suppl 2):122. doi: 10.1186/s13052-018-0560-3.</mixed-citation><mixed-citation xml:lang="en">Boffi L, Russo P Limongelli G. Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists. Ital J Pediatr. 2018;44 (Suppl 2):122. doi: 10.1186/s13052-018-0560-3.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Мукополисахаридоз I типа у детей. Клинические рекомендации [интернет]. — М.: Союз педиатров России, 2016. Доступно по: http://www.pediatr-russia.ru/sites/default/files/file/kr_mps1.pdf. Ссылка активна на 12.08.2019.</mixed-citation><mixed-citation xml:lang="en">Mukopolisakharidoz I tipa u detey. Klinicheskie rekomendatsii [Internet]. Moscow: Soyuz pediatrov Rossii; 2016. (In Russ). Доступно по: http://www.pediatr-russia.ru/sites/default/files/file/kr_mps1.pdf. Ссылка активна на 12.08.2019.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Вашакмадзе Н.Д. Мультидисциплинарные принципы ведения детей с мукополисахаридозами в повышении эффективности их диагностики и лечения: Автореф. дис. ... д-ра мед. наук. — Екатеринбург, 2019. — 48 с. Доступно по: https://rusneb.ru/catalog/000199_000009_008703814/. Ссылка активна на 14.03.2019.</mixed-citation><mixed-citation xml:lang="en">Vashakmadze ND. Mul’tidistsiplinarnyye printsipy vedeniya detey s mukopolisakharidozami v povyshenii effektivnosti ikh diagnostiki i lecheniya. [dissertation abstract] Ekaterinburg; 2019. 48 р. (In Russ). Доступно по: https://rusneb.ru/catalog/000199_000009_008703814/. Ссылка активна на 14.03.2019.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Parini R, Bertola F, Russo P. Molecular basis diagnosis and clinical management of mupolysaccharidoses. Cardiogenetics. 2013; 3(s1):e2. doi: 10.4081/cardiogenetics.2013.s1.e2.</mixed-citation><mixed-citation xml:lang="en">Parini R, Bertola F, Russo P. Molecular basis diagnosis and clinical management of mupolysaccharidoses. Cardiogenetics. 2013; 3(s1):e2. doi: 10.4081/cardiogenetics.2013.s1.e2.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Russo P, Andria G, Baldinelli A, et al. Cardiologists and mucopolysaccharidoses. Recommendations of GICEM (Cardiology Experts on Metabolic Disease Italian Group) for diagnosis, follow-up and cardiological management. G Ital Cardiol (Rome). 2017;18(9):638-649. doi: 10.1714/2741.27947.</mixed-citation><mixed-citation xml:lang="en">Russo P, Andria G, Baldinelli A, et al. Cardiologists and mucopolysaccharidoses. Recommendations of GICEM (Cardiology Experts on Metabolic Disease Italian Group) for diagnosis, follow-up and cardiological management. G Ital Cardiol (Rome). 2017;18(9):638-649. doi: 10.1714/2741.27947.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Braunlin E, Tolar J, Mackey-Bojack S, et.al. Clear cells in the atrioventricular valves of infants with severe human mucopolysaccharidosis (hurler syndrome) are activated valvular interstitial cells. Cardiovascular Pathol. 2011;20:315-321. doi: 10.1016/j.carpath.2010.06.004.</mixed-citation><mixed-citation xml:lang="en">Braunlin E, Tolar J, Mackey-Bojack S, et.al. Clear cells in the atrioventricular valves of infants with severe human mucopolysaccharidosis (hurler syndrome) are activated valvular interstitial cells. Cardiovascular Pathol. 2011;20:315-321. doi: 10.1016/j.carpath.2010.06.004.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Довгань М.И., Белозеров Ю.М., Семячкина А.Н. Поражение сердца при мукополисахаридозах // Российский вестник перинатологии и педиатрии. — 2014. — Т. 59. — № 3. — С. 22-31.</mixed-citation><mixed-citation xml:lang="en">Dovgan MI, Belozerov YuM, Semyachkina AN. Heart damage in mucopolysaccharidosis. Rossiyskiy vestnik perinatologii i pediatrii. 2014;59(3):22-31. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wiseman DH, Mercer J, Tylee K, et al. Management of mucopolysaccharidosis type IH (Hurler's syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution's experience. Inherit Metab Dis. 2013;36(2):263-270. doi: 10.1007/s10545-012-9500-3.</mixed-citation><mixed-citation xml:lang="en">Wiseman DH, Mercer J, Tylee K, et al. Management of mucopolysaccharidosis type IH (Hurler's syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution's experience. Inherit Metab Dis. 2013;36(2):263-270. doi: 10.1007/s10545-012-9500-3.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hirth A, Berg A, Greve G. Successful treatment of severe heart failure in an infant with Hurler syndrome. J Inherit Metab Dis. 2007; 30(5):820. doi: 10.0007/s10545-007-0613-z.</mixed-citation><mixed-citation xml:lang="en">Hirth A, Berg A, Greve G. Successful treatment of severe heart failure in an infant with Hurler syndrome. J Inherit Metab Dis. 2007; 30(5):820. doi: 10.0007/s10545-007-0613-z.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidasa). Pediatrics. 2007;120(1):e37-46. doi: 10.1542/peds.2006-2156.</mixed-citation><mixed-citation xml:lang="en">Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidasa). Pediatrics. 2007;120(1):e37-46. doi: 10.1542/peds.2006-2156.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
